FindTrial
Sign In

Randomized trial to Compare Ropivacaine/Dexamethasone and 10% Lignocaine Injection in Distal Glossopharyngeal Nerve Block for Intractable Cancer Pain

Comparison between Ropivacaine/Dexamethasone and 10% Lignocaine Injection in Distal Glossopharyngeal Nerve Block for Intractable Cancer Pain- A Randomised Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020712
Enrollment
60
Registered
2019-08-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C01- Malignant neoplasm of base of tongue Health Condition 2: C10- Malignant neoplasm of oropharynx Health Condition 3: C05- Malignant neoplasm of palate Health Condition 4: C09- Malignant neoplasm of tonsil

Interventions

Intervention1: 10% Lignocaine: A single dose of 4ml of 10% Lignocaine will be injected in the intermuscular plane around the distal nerve in the neck. Control Intervention1: Ropivacaine/Dexamethasone:

Sponsors

Mukesh Yadav
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Age > 18years b) Patients with proven carcinoma of the oropharynx and supraglottic larynx with estimated survival of 3 months or more. c) Pain lasting for at least 2 weeks with an average intensity of 5 or more on an 11-point numeric rating scale (NRS) refractory to a combination strong opioids and NSAIDS

Exclusion criteria

Exclusion criteria: 5.3. Exclusion criteria a) Local infection or skin ulceration at the puncture site b) Local anaesthetic allergy c) Psychiatric illness that affected cooperation.

Design outcomes

Primary

MeasureTime frame
Primary efficacy outcome: is pain reduction at week 4, on the basis of the NRS (average pain in the last 24 hours from 0, indicating no pain, to 10 maximal pain) Primary safety outcome: All adverse events will be recorded throughout the study and then were judged for potential association with injections. Timepoint: 1, 2 and 4 weeks—

Secondary

MeasureTime frame
1.The Brief Pain Inventory-short form Hindi/English14 (Instrument for patients with cancer to evaluate pain severity and functional interference) 2. WHO Quality of Life-BREF (WHOQOL-BREF) Hindi/English â?? quality of life. 3. Patient Global Impression of Change (PGIC)15 for Global ratings by patients of their improvement and satisfaction with treatment. 4. Clinical Global Impression of Change (CGIC)16 5. Analgesic requirement and rescue analgesic requirement. Timepoint: at 4 weeks—

Countries

India

Contacts

Public ContactMukesh Yadav

AIIMS

mukeshyadav11@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026